The emergence of a unique population in non-small cell lung cancer: Systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy

Seminars in Oncology

Volumn 33, Issue SUPPL. 1, 2006, Pages 32-38

  Socinski, Mark A ^a   Stinchcombe, Thomas E ^a   Hayes, D Neil ^a   Morris, David E ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; VINBLASTINE; VINDESINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESEARCH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG SAFETY; HUMAN; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSTOPERATIVE CARE; PRIORITY JOURNAL; REACTION TIME; RECURRENT DISEASE; REVIEW; SOLID TUMOR; SURVIVAL RATE;

EID: 32044466928     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.12.006     Document Type: Article

References (43)

1. American Cancer Society Cancer facts and figures 2004 Available at: http://www.cancer.org/downloads/STT/CAFF_finalPWSecured.pdf (accessed Nov 28, 2005)
2. C. Mountain Revisions in the International System for Staging Lung Cancer Chest 111 1997 1710 1717
3. D. Jones, F. Detterbeck Surgery for stage I non-small cell lung cancer F.C. Detterbeck M.P. Rivera M.A. Socinski J.G. Rosenman Diagnosis and Treatment of Lung Cancer An Evidence-Based Guide for the Practicing Clinician 2001 Saunders Philadelphia, PA pp 177-190
4. F. Detterbeck, T. Egan Surgery for stage II non-small cell lung cancer F.C. Detterbeck M.P. Rivera M.A. Socinski J.G. Rosenman Diagnosis and Treatment of Lung Cancer An Evidence-Based Guide for the Practicing Clinician 2001 Saunders Philadelphia, PA pp 191-197
5. F. Detterbeck, D. Jones Surgical treatment of stage IIIA (N2) non-small cell lung cancer F.C. Detterbeck M.P. Rivera M.A. Socinski J.G. Rosenman Diagnosis and Treatment of Lung Cancer An Evidence-Based Guide for the Practicing Clinician 2001 Saunders Philadelphia, PA pp 244-256
6. R.H. Blum Adjuvant chemotherapy for lung cancer - A new standard of care N Engl J Med 350 2004 404 405
7. K.M. Pisters Adjuvant chemotherapy for non-small-cell lung cancer - The smoke clears N Engl J Med 352 2005 2640 2642
8. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer A meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ 311 1995 899 909
9. S. Keller, S. Adak, H. Wagner A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II and IIIA non-small-cell lung cancer Eastern Cooperative Oncology Group N Engl J Med 343 2000 1217 1222
10. G.V. Scagliotti, R. Fossati, V. Torri Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer J Natl Cancer Inst 95 2003 1453 1461
11. D. Waller, M.D. Peake, R.J. Stephens Chemotherapy for patients with non-small cell lung cancer The surgical setting of the Big Lung Trial Eur J Cardiothorac Surg 26 2004 173 182
12. R. Arriagada, B. Bergman, A. Dunant Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
13. G. Strauss, J.E. Herndon, M. Maddaus Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC) Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 J Clin Oncol 22 suppl 14s 2004 621s (abstr 7019)
14. T. Winton, R. Livingston, D. Johnson Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 2005 2589 2597
15. J. Douillard, R. Rosell, M. Delena Adjuvant Navelbine International Trialist Association ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up J Clin Oncol 23 suppl 16s 2005 624 (abstr 7013)
16. M.A. Socinski, F.C. Detterbeck, J.G. Rosenman Adjuvant therapy for resected non-small cell lung cancer F.C. Detterbeck M.P. Rivera M.A. Socinski J.G. Rosenman Diagnosis and Treatment of Lung Cancer An Evidence-Based Guide for the Practicing Clinician 2001 Saunders Philadelphia, PA pp 206-219
17. D.G. Pfister, D.H. Johnson, C.G. Azzoli American Society of Clinical Oncology Treatment of Unresectable Non-Small Cell Lung Cancer Guideline Update 2003 J Clin Oncol 22 2004 330 353
18. F.A. Shepherd, J. Dancey, R. Ramlau Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
19. F.V. Fossella, R. DeVore, R.N. Kerr Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens The TAX 320 Non-Small Cell Lung Cancer Study Group J Clin Oncol 18 2000 2354 2362
20. N. Hanna, F.A. Shepherd, F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
21. F. Shepherd, J.R. Pereira, T. Ciuleanu A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial J Clin Oncol 22 suppl 14s 2004 622s (abstr 7022)
22. M.G. Kris, R.B. Natale, R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer A randomized trial JAMA 290 2003 2149 2158
23. G. Blackledge, F. Lawton, C. Redman Response of patients in phase II studies of chemotherapy in ovarian cancer Implications for patient treatment and the design of phase II trials Br J Cancer 59 1989 650 653
24. M.E. Gore, I. Fryatt, E. Wiltshaw Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol Oncol 36 1990 207 211
25. M. Markman, J. Markman, K. Webster Duration of response to second-line, platinum-based chemotherapy for ovarian cancer Implications for patient management and clinical trial design J Clin Oncol 22 2004 3120 3125
26. M. Markman, R. Rothman, T. Hakes Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 1991 389 393
27. R.M. Goldberg, D.J. Sargent, R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 2004 23 30
28. E.P. Winer, D.A. Berry, S. Woolf Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer Cancer and Leukemia Group B trial 9342 J Clin Oncol 22 2004 2061 2068
29. C. Zielinski, S. Beslija, Z. Mrsic-Krmpotic Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer A Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial J Clin Oncol 23 2005 1401 1408
30. Y.J. Chua, C. Steer, D. Yip Recent advances in management of small-cell lung cancer Cancer Treat Rev 30 2004 521 543
31. T. Hoang, R. Xu, H. Schiller A clinical model to predict survival in chemonaive patients with advanced non-small cell lung cancer (NSCLC) treated with standard chemotherapy Eastern Cooperative Oncology Group (ECOG) data J Clin Oncol 23 2005 175 183
32. N. Green, W. Kern The clinical course and treatment results of patients with postresection locally recurrent lung cancer Cancer 42 1978 2478 2482
33. W.J. Curran Jr, S.H. Herbert, P.M. Stafford Should patients with post-resection locoregional recurrence of lung cancer receive aggressive therapy? Int J Radiat Oncol Biol Phys 24 1992 25 30
34. J. Leung, D. Ball, T. Worotniuk Survival following radiotherapy for post-surgical locoregional recurrence of non-small cell lung cancer Lung Cancer 13 1995 121 127
35. K. Hotta, I. Sekine, K. Suzuki Distant failure after treatment of postoperative locoregional recurrence of non-small cell lung cancer Thorac Cardiovasc Surg 51 2003 283 287
36. B. Jeremic, M. Bamberg External beam radiation therapy for bronchial stump recurrence of non-small-cell lung cancer after complete resection Radiother Oncol 64 2002 251 257
37. F.C. Detterbeck, D.R. Jones, K.H. Kernstine Lung cancer Special treatment issues Chest 123 suppl 1 2003 244 258
38. T.M. Aziz, R.A. Saad, J. Glasser The management of second primary lung cancers A single centre experience in 15 years Eur J Cardiothorac Surg 21 2002 527 533
39. N. Martini, M.R. Melamed Multiple primary lung cancers J Thorac Cardiovasc Surg 70 1975 606 612
40. Y. Ichinose, N. Hara, M. Ohta DNA ploidy patterns of tumors diagnosed as metachronous or recurrent lung cancers Ann Thorac Surg 52 1991 469 473
41. D. Brinkmann, A. Ryan, A. Ayhan A molecular genetic and statistical approach for the diagnosis of dual-site cancers J Natl Cancer Inst 96 2004 1441 1446
42. K. Hiroshima, T. Toyozaki, H. Kohno Synchronous and metachronous lung carcinomas Molecular evidence for multicentricity Pathol Int 48 1998 869 876
43. Y. Nonami, Y. Ohtuki, S. Sasaguri Study of the diagnostic difference between the clinical diagnostic criteria and results of immunohistochemical staining of multiple primary lung cancers J Cardiovasc Surg 44 2003 661 665